-transparent.png){kind=logo}
Tumor necrosis factor-alpha (TNF-alpha) is thought to induce cachexia in subjects infected with human immunodeficiency virus (HIV), and it has been suggested that HIV-seropositive patients would benefit from treatment with pentoxifylline, a known suppressor of TNF-alpha production. The purpose of the present study was to examine how pentoxifylline at a dose of 800 mg thrice daily would influence the cellular immune system in HIV-seropositive persons with elevated TNF-alpha. Six HIV-seropositive subjects with elevated amounts of TNF-alpha in plasma at least at two occasions were included in an open, controlled, randomized, cross-over study consisting of a 6 week treatment period and a 6 week control period. Blood samples were collected before and at the end of each period. Pentoxifylline treatment did not influence the concentration of plasma-TNF-alpha, subpopulations of blood mononuclear cells, the proliferative responses nor the natural killer (NK), and lymphokine activated killer (LAK) cell activities. Furthermore, pentoxifylline treatment did not influence the weight, temperature, well being, or tiredness of the subjects. However, the patients frequently reported gastrointestinal side effects. In vitro, however, pentoxifylline at suprapharmacological concentrations inhibited the blood mononuclear cell (BMNC) proliferative responses, NK, and LAK cell activities.
A Kruse, and
K Rieneck, and
M Kappel, and
M Orholm, and
H Bruunsgaard, and
H Ullum, and
P Skinhøj, and
B K Pedersen
January 1993,
Renal failure,
A Kruse, and
K Rieneck, and
M Kappel, and
M Orholm, and
H Bruunsgaard, and
H Ullum, and
P Skinhøj, and
B K Pedersen
December 1988,
Rivista europea per le scienze mediche e farmacologiche = European review for medical and pharmacological sciences = Revue europeenne pour les sciences medicales et pharmacologiques,
A Kruse, and
K Rieneck, and
M Kappel, and
M Orholm, and
H Bruunsgaard, and
H Ullum, and
P Skinhøj, and
B K Pedersen
February 1988,
British journal of haematology,
A Kruse, and
K Rieneck, and
M Kappel, and
M Orholm, and
H Bruunsgaard, and
H Ullum, and
P Skinhøj, and
B K Pedersen
June 1995,
African journal of medicine and medical sciences,
A Kruse, and
K Rieneck, and
M Kappel, and
M Orholm, and
H Bruunsgaard, and
H Ullum, and
P Skinhøj, and
B K Pedersen
July 1999,
AIDS (London, England),
A Kruse, and
K Rieneck, and
M Kappel, and
M Orholm, and
H Bruunsgaard, and
H Ullum, and
P Skinhøj, and
B K Pedersen
January 2000,
Psychological medicine,
A Kruse, and
K Rieneck, and
M Kappel, and
M Orholm, and
H Bruunsgaard, and
H Ullum, and
P Skinhøj, and
B K Pedersen
October 1996,
The Journal of infectious diseases,
A Kruse, and
K Rieneck, and
M Kappel, and
M Orholm, and
H Bruunsgaard, and
H Ullum, and
P Skinhøj, and
B K Pedersen
January 2008,
Journal of the International Academy of Periodontology,
A Kruse, and
K Rieneck, and
M Kappel, and
M Orholm, and
H Bruunsgaard, and
H Ullum, and
P Skinhøj, and
B K Pedersen
September 1988,
Lancet (London, England),
A Kruse, and
K Rieneck, and
M Kappel, and
M Orholm, and
H Bruunsgaard, and
H Ullum, and
P Skinhøj, and
B K Pedersen
December 1989,
Australian and New Zealand journal of medicine,
